China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd for its steep pulse therapy equipment and disposable steep pulse ablation needle, as reported on the bureau’s website. This marks a significant advancement in the field of minimally invasive interventional treatments for tumors in China.
Introducing the Steep Pulse Therapy Device
The steep pulse therapy device is a groundbreaking technology used in conjunction with a disposable steep pulse ablation needle and connecting wire set. Both products represent the first home-grown minimally invasive interventional treatment for tumors in China. This new technology offers a non-thermal ablation method that allows the ablation needle to puncture the target area through the skin, generating a high-voltage pulsed electric field.
Achieving Ablation of Malignant Solid Tumors
The high-voltage pulsed electric field caused by the steep pulse therapy device leads to an irreversible perforation effect and rapid apoptosis of cells, effectively ablating malignant solid tumors of the liver. This innovative approach provides a new tool in the arsenal against cancer, offering patients a minimally invasive treatment option with the potential for improved outcomes and reduced side effects compared to traditional thermal ablation methods.-Fineline Info & Tech
